EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The Arylamine N-Acetyltransferases as Therapeutic Targets in Metabolic Diseases Associated with Mitochondrial Dysfunction

Chandra Choudhury, Melinder K Gill, Courtney E McAleese, Neville J Butcher, Shyuan T Ngo, Frederik J Steyn, Rodney F Minchin iD

Pharmacological Reviews · 2024

DOI: 10.1124/pharmrev.123.000835 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacological Reviews, 2024. Verfasst von Chandra Choudhury und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences (C.C., M.K.G., C.E.M., N.J.B., F.J.S., R.F.M.) and Australian Institute for Bioengineering and Nanotechnology (S.T.N.),…. Hauptthemen laut MEDLINE: Arylamine N-Acetyltransferase, Metabolic Diseases, Mitochondrial Diseases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 244 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In humans, there are two arylamine N-acetyltransferase genes that encode functional enzymes (NAT1 and NAT2) as well as one pseudogene, all of which are located together on chromosome 8. Although they were first identified by their role in the acetylation of drugs and other xenobiotics, recent studies have shown strong associations for both enzymes in a variety of diseases, including cancer, cardiovascular disease, and diabetes. There is growing evidence that this association may be causal. Consistently, NAT1 and NAT2 are shown to be required for healthy mitochondria. This review discusses the current literature on the role of both NAT1 and NAT2 in mitochondrial bioenergetics. It will attempt to relate our understanding of the evolution of the two genes with biologic function and then present evidence that several major metabolic diseases are influenced by NAT1 and NAT2. Finally, it will discuss current and future approaches to inhibit or enhance NAT1 and NAT2 activity/expression using small-molecule drugs. SIGNIFICANCE STATEMENT: The arylamine N-acetyltransferases (NATs) NAT1 and NAT2 share common features in their associations with mitochondrial bioenergetics. This review discusses mitochondrial function as it relates to health and disease, and the importance of NAT in mitochondrial function and dysfunction. It also compares NAT1 and NAT2 to highlight their functional similarities and differences. Both NAT1 and NAT2 are potential drug targets for diseases where mitochondrial dysfunction is a hallmark of onset and progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arylamine N-AcetyltransferaseMetabolic DiseasesMitochondrial DiseasesHumansAcetyltransferasesSubstrate Specificity

Substanzen

Arylamine N-AcetyltransferaseAcetyltransferasesNAT2 protein, human

Autor:innen und Institutionen

  • School of Biomedical Sciences (C.C., M.K.G., C.E.M., N.J.B., F.J.S., R.F.M.) and Australian Institute for Bioengineering and Nanotechnology (S.T.N.), University of Queensland, Brisbane, Australia.

ORCID-Profile: Rodney F Minchin

Zitieren

APA

Choudhury, C., Gill, M. K., McAleese, C. E., Butcher, N. J., Ngo, S. T., Steyn, F. J., & Minchin, R. F. (2024). The Arylamine N-Acetyltransferases as Therapeutic Targets in Metabolic Diseases Associated with Mitochondrial Dysfunction. Pharmacological Reviews. https://doi.org/10.1124/pharmrev.123.000835

Vancouver

Choudhury C, Gill MK, McAleese CE, Butcher NJ, Ngo ST, Steyn FJ, et al. The Arylamine N-Acetyltransferases as Therapeutic Targets in Metabolic Diseases Associated with Mitochondrial Dysfunction. Pharmacological Reviews. 2024. doi:10.1124/pharmrev.123.000835

BibTeX
@article{Choudhury2024,
  author = {Choudhury, Chandra and Gill, Melinder K and McAleese, Courtney E and Butcher, Neville J and Ngo, Shyuan T and Steyn, Frederik J and Minchin, Rodney F},
  title = {The Arylamine N-Acetyltransferases as Therapeutic Targets in Metabolic Diseases Associated with Mitochondrial Dysfunction},
  journal = {Pharmacological Reviews},
  year = {2024},
  doi = {10.1124/pharmrev.123.000835}
}
Kostenlos starten →